BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call

Conference call scheduled for March 07, 2019 at 8:30 AM ET

NEW HAVEN, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on Thursday, March 07, 2019. The Company will hold a conference call at 8:30 AM Eastern Time on Thursday, March 07, 2019 to discuss the financial results and provide a business update.

CONFERENCE CALL & WEBCAST-
Thursday, March 07, 2019, 8:30 a.m. Eastern Time

Domestic: 888-224-1005
International:  323-794-2551
Conference ID:  2090253
Webcast:  http://public.viavid.com/index.php?id=133482
Replay – Available through April 7, 2019
Domestic:      844-512-2921
International:    412-317-6671
Conference ID:    2090253


About BioXcel Therapeutics, Inc. (BTI):

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:
The Ruth Group for BTI:
Lee Roth / Janhavi Mohite
646-536-7012 / 7026
lroth@theruthgroup.com  / jmohite@theruthgroup.com 

Source: BioXcel Therapeutics, Inc.